Skip to main content
SpringerLink
Log in

Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head- to- head study

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

No head- to- head comparisons are available to analyze the efficacy of octreotide (LAR) and lanreotide (LAN) as first-line treatment of acromegaly. We compared the efficacy of these two drugs in 54 newly diagnosed patients (21 women, 33 men), 27 treated with LAR (10–30 mg every 28 days) and 27 with LAN (60–90 mg/28 days), for 12 months. Each LAR-treated patient was matched with one LAN-treated patient as for GH levels, sex, and age (± 5 yr). Outcome measures were GH and IGF-I levels and tumor shrinkage and secondarily classical cardiovascular risk factors (total/HDL-cholesterol ratio, glucose tolerance), blood pressure and drug tolerability. In LAR- and in LAN-treated patients, respectively: GH and IGF- I were controlled in 21 (77.7%) and in 16 patients (59.3%; p=0.26); tumor shrinkage was absent (<25%) in 4 and 5 patients (p=1), mild (25.1–50%) in 9 and 12 (p=0.57), moderate (50.1–75%) in 10 and 6 (p=0.37) and notable (>75%) in 4 and 4 patients (p=1). The total/HDL-cholesterol ratio and insulin levels significantly decreased while glucose levels significantly increased in both groups. None of the patients with normal glucose tolerance at diagnosis developed diabetes mellitus. Side effects were mostly at the gastrointestinal level and were similar with both drugs. In conclusion, newly diagnosed patients with acromegaly treated with LAR and LAN have no significantly different prevalence of disease control, tumor shrinkage, improvement of cardiovascular risk markers and side effects. Therefore, both drugs can be safely employed as first-line therapy of acromegaly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Melmed S, Casanueva FF, Cavagnini F, et al.; Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002, 87: 4054–8.

    Article  PubMed  CAS  Google Scholar 

  2. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 387–99.

    Article  Google Scholar 

  3. Bevan JS. The anti-tumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856–63.

    Article  PubMed  CAS  Google Scholar 

  4. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 4405–10.

    Article  PubMed  CAS  Google Scholar 

  5. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.

    Article  PubMed  CAS  Google Scholar 

  6. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-actings analog therapy of acromegaly: a metaanalysis. J Clin Endocrinol Metab 2005, 90: 4465–73.

    Article  PubMed  CAS  Google Scholar 

  7. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999, 141: 267–71.

    Article  PubMed  CAS  Google Scholar 

  8. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 1999, 51: 275–80.

    Article  CAS  Google Scholar 

  9. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000, 53: 577–86.

    Article  CAS  Google Scholar 

  10. Kendall-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M. Long acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000, 3: 61–5.

    Article  PubMed  CAS  Google Scholar 

  11. Giusti M, Sessarego P, Timossi G, Bocca L. Slow-release lanreotide and octreotide LAR in the medical therapy of acromegaly. Eur J Endocrinol 2000, 142: 697–8.

    Article  PubMed  CAS  Google Scholar 

  12. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002, 56: 65–71.

    Article  CAS  Google Scholar 

  13. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004, 150: 489–95.

    Article  PubMed  Google Scholar 

  14. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004, 151: 317–24.

    Article  PubMed  CAS  Google Scholar 

  15. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metabol 2001, 86: 2779–86.

    CAS  Google Scholar 

  16. Colao A, Pivonello R, Cappabianca P, et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 342–9.

    Article  CAS  Google Scholar 

  17. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1197, 82: 3308–14.

    Article  Google Scholar 

  18. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526–9.

    PubMed  CAS  Google Scholar 

  19. Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996, 81: 2356–62.

    PubMed  CAS  Google Scholar 

  20. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998, 352: 1455–61.

    Article  PubMed  CAS  Google Scholar 

  21. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91: 2112–8.

    Article  PubMed  CAS  Google Scholar 

  22. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996, 124 (Suppl): S1–9.

    Article  PubMed  CAS  Google Scholar 

  23. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110: 227–39.

    Article  PubMed  Google Scholar 

  24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  PubMed  CAS  Google Scholar 

  25. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005, 63: 470–6.

    Article  Google Scholar 

  26. The Seventh Report Of The Joint National Committee On Prevention, Detection, Evaluation And Treatment Of High Blood Pressure: the JNC report. JAMA 2003, 289: 2560–1.

    Article  Google Scholar 

  27. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of slowrelease lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999, 84: 527–32.

    PubMed  CAS  Google Scholar 

  28. Manelli F, Desenzani P, Boni E, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999, 2: 205–10.

    Article  PubMed  CAS  Google Scholar 

  29. Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999, 83: 1506–9, A8.

    Article  PubMed  CAS  Google Scholar 

  30. Freda PU. Somatostatin analogues in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013–8.

    Article  PubMed  CAS  Google Scholar 

  31. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000, 53:719–24.

    Article  CAS  Google Scholar 

  32. Colao A, Marzullo P, Cuocolo A. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide. Clin Endocrinol (Oxf) 2003, 58: 169–76.

    Article  CAS  Google Scholar 

  33. Colao A, Cuocolo A, Marzullo P, et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999, 84: 17–23.

    Article  PubMed  CAS  Google Scholar 

  34. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 2001, 86: 1551–7.

    PubMed  CAS  Google Scholar 

  35. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990,113: 921–5.

    Article  PubMed  CAS  Google Scholar 

  36. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992, 117: 719–26.

    Article  PubMed  CAS  Google Scholar 

  37. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 2005, 4: 43–53.

    Article  PubMed  CAS  Google Scholar 

  38. Ronchi CL, Varca V, Giavoli C, et al. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 2005, 90: 1377–82.

    Article  PubMed  CAS  Google Scholar 

  39. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002, 25: 502–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, “Federico II” University of Naples, via S. Pansini 5, 80131, Naples, Italy

    R. S. Auriemma, R. Pivonello, M. Galdiero, M. C. De Martino, M. De Leo, G. Lombardi & A. Colao MD, PhD

  2. Section of Endocrinology, Italian Auxologic Institute, University of Milan, Milan, Italy

    G. Vitale

Authors
  1. R. S. Auriemma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Galdiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. C. De Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. De Leo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Colao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Colao MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Auriemma, R.S., Pivonello, R., Galdiero, M. et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head- to- head study. J Endocrinol Invest 31, 956–965 (2008). https://doi.org/10.1007/BF03345632

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345632

Key Words

Search

Navigation